Reuters logo
BRIEF-Cellectis announces first administration in Phase I clinical study in AML for UCART123
June 28, 2017 / 5:33 AM / 4 months ago

BRIEF-Cellectis announces first administration in Phase I clinical study in AML for UCART123

June 28 (Reuters) - CELLECTIS SA:

* ANNOUNCED ON TUESDAY FIRST ADMINISTRATION IN THE PHASE I CLINICAL STUDY IN ACUTE MYELOID LEUKEMIA (AML) FOR ITS INVESTIGATIONAL PRODUCT UCART123

Source text for Eikon:

Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below